Litcius/Paper detail

Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial

Robert J. Motzer, Thomas Powles, Mauricio Burotto, Bernard Escudier, María T. Bourlon, Amishi Y. Shah, Cristina Suárez, Alketa Hamzaj, Camillo Porta, Christopher Hocking, Elizabeth R. Kessler, Howard Gurney, Yoshihiko Tomita, Jens Bedke, Joshua Zhang, Burçin Şimşek, Christian Scheffold, Andrea B. Apolo, Toni K. Choueiri

2022The Lancet Oncology307 citationsDOIOpen Access PDF

Topics & Concepts

CabozantinibSunitinibMedicineNivolumabRenal cell carcinomaClinical endpointInternal medicineKidney cancerOncologyProgression-free survivalResponse Evaluation Criteria in Solid TumorsCancerPhases of clinical researchClinical trialUrologyImmunotherapyOverall survivalRenal cell carcinoma treatmentFerroptosis and cancer prognosisCancer Immunotherapy and Biomarkers
Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial | Litcius